Global Tumor Necrosis Factor Inhibitors Drug Market Insights and Forecast to 2031

Report ID: 1564405 | Published Date: Jan 2025 | No. of Page: 127 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Tumor Necrosis Factor Inhibitors Drug Product Introduction
    1.2 Market by Type
        1.2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Cimzia (Certolizumab Pegol)
        1.2.3 Enbrel (Etanercept)
        1.2.4 Humira ( Adalimumab)
        1.2.5 Otezla (Apremilast)
        1.2.6 Remicade (Infliximab)
        1.2.7 Simponi (Golimumab)
    1.3 Market by Application
        1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Estimates and Forecasts 2017-2028
    2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Estimates and Forecasts 2017-2028
    2.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region
        2.4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2017-2022)
        2.4.2 Global Sales Tumor Necrosis Factor Inhibitors Drug by Region (2023-2028)
    2.5 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region
        2.5.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2017-2022)
        2.5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers
        3.1.1 Global Top Tumor Necrosis Factor Inhibitors Drug Manufacturers by Sales (2017-2022)
        3.1.2 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Tumor Necrosis Factor Inhibitors Drug in 2021
    3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers
        3.2.1 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2017-2022)
        3.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Inhibitors Drug Revenue in 2021
    3.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type
        4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Sales by Type (2017-2022)
        4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Sales by Type (2023-2028)
        4.1.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2028)
    4.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type
        4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Revenue by Type (2017-2022)
        4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2017-2028)
    4.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Type
        4.3.1 Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2017-2022)
        4.3.2 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Application
        5.1.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Sales by Application (2017-2022)
        5.1.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Sales by Application (2023-2028)
        5.1.3 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2028)
    5.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application
        5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Historical Revenue by Application (2017-2022)
        5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2017-2028)
    5.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Application
        5.3.1 Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2017-2022)
        5.3.2 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Type
        6.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2028)
        6.1.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2028)
    6.2 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Application
        6.2.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2028)
        6.2.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2028)
    6.3 North America Tumor Necrosis Factor Inhibitors Drug Market Size by Country
        6.3.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2028)
        6.3.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Type
        7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2028)
        7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2028)
    7.2 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Application
        7.2.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2028)
        7.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2028)
    7.3 Europe Tumor Necrosis Factor Inhibitors Drug Market Size by Country
        7.3.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2028)
        7.3.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Type
        8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2028)
        8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2028)
    8.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Application
        8.2.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2028)
        8.2.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2028)
    8.3 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Market Size by Region
        8.3.1 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2017-2028)
        8.3.2 Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Type
        9.1.1 Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2028)
        9.1.2 Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2028)
    9.2 Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Application
        9.2.1 Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2028)
        9.2.2 Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2028)
    9.3 Latin America Tumor Necrosis Factor Inhibitors Drug Market Size by Country
        9.3.1 Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2028)
        9.3.2 Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Type
        10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2028)
    10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Application
        10.2.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2028)
    10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Market Size by Country
        10.3.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Apogenix
        11.1.1 Apogenix Corporation Information
        11.1.2 Apogenix Overview
        11.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Apogenix Recent Developments
    11.2 AryoGen Biopharma
        11.2.1 AryoGen Biopharma Corporation Information
        11.2.2 AryoGen Biopharma Overview
        11.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 AryoGen Biopharma Recent Developments
    11.3 Bionovis
        11.3.1 Bionovis Corporation Information
        11.3.2 Bionovis Overview
        11.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Bionovis Recent Developments
    11.4 CASI Pharmaceuticals
        11.4.1 CASI Pharmaceuticals Corporation Information
        11.4.2 CASI Pharmaceuticals Overview
        11.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 CASI Pharmaceuticals Recent Developments
    11.5 Celltrion
        11.5.1 Celltrion Corporation Information
        11.5.2 Celltrion Overview
        11.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Celltrion Recent Developments
    11.6 Celgene Corporation
        11.6.1 Celgene Corporation Corporation Information
        11.6.2 Celgene Corporation Overview
        11.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Celgene Corporation Recent Developments
    11.7 Delenex Therapeutics
        11.7.1 Delenex Therapeutics Corporation Information
        11.7.2 Delenex Therapeutics Overview
        11.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Delenex Therapeutics Recent Developments
    11.8 Dexa Medica
        11.8.1 Dexa Medica Corporation Information
        11.8.2 Dexa Medica Overview
        11.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Dexa Medica Recent Developments
    11.9 EPIRUS Biopharmaceuticals
        11.9.1 EPIRUS Biopharmaceuticals Corporation Information
        11.9.2 EPIRUS Biopharmaceuticals Overview
        11.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 EPIRUS Biopharmaceuticals Recent Developments
    11.10 Janssen Biotech
        11.10.1 Janssen Biotech Corporation Information
        11.10.2 Janssen Biotech Overview
        11.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Janssen Biotech Recent Developments
    11.11 GlaxoSmithKline
        11.11.1 GlaxoSmithKline Corporation Information
        11.11.2 GlaxoSmithKline Overview
        11.11.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 GlaxoSmithKline Recent Developments
    11.12 HanAll Biopharma
        11.12.1 HanAll Biopharma Corporation Information
        11.12.2 HanAll Biopharma Overview
        11.12.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 HanAll Biopharma Recent Developments
    11.13 Intas Pharmaceuticals
        11.13.1 Intas Pharmaceuticals Corporation Information
        11.13.2 Intas Pharmaceuticals Overview
        11.13.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.13.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.13.5 Intas Pharmaceuticals Recent Developments
    11.14 LEO Pharma
        11.14.1 LEO Pharma Corporation Information
        11.14.2 LEO Pharma Overview
        11.14.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.14.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.14.5 LEO Pharma Recent Developments
    11.15 LG Life Sciences
        11.15.1 LG Life Sciences Corporation Information
        11.15.2 LG Life Sciences Overview
        11.15.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.15.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.15.5 LG Life Sciences Recent Developments
    11.16 MedImmune
        11.16.1 MedImmune Corporation Information
        11.16.2 MedImmune Overview
        11.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.16.5 MedImmune Recent Developments
    11.17 Momenta Pharmaceuticals
        11.17.1 Momenta Pharmaceuticals Corporation Information
        11.17.2 Momenta Pharmaceuticals Overview
        11.17.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.17.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.17.5 Momenta Pharmaceuticals Recent Developments
    11.18 Novartis
        11.18.1 Novartis Corporation Information
        11.18.2 Novartis Overview
        11.18.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.18.4 Novartis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.18.5 Novartis Recent Developments
    11.19 PROBIOMED
        11.19.1 PROBIOMED Corporation Information
        11.19.2 PROBIOMED Overview
        11.19.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.19.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.19.5 PROBIOMED Recent Developments
    11.20 Reliance Life Sciences
        11.20.1 Reliance Life Sciences Corporation Information
        11.20.2 Reliance Life Sciences Overview
        11.20.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.20.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.20.5 Reliance Life Sciences Recent Developments
    11.21 Sandoz
        11.21.1 Sandoz Corporation Information
        11.21.2 Sandoz Overview
        11.21.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.21.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.21.5 Sandoz Recent Developments
    11.22 Samsung Bioepis
        11.22.1 Samsung Bioepis Corporation Information
        11.22.2 Samsung Bioepis Overview
        11.22.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.22.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.22.5 Samsung Bioepis Recent Developments
    11.23 Sanofi-Aventis
        11.23.1 Sanofi-Aventis Corporation Information
        11.23.2 Sanofi-Aventis Overview
        11.23.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.23.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.23.5 Sanofi-Aventis Recent Developments
    11.24 Shanghai CP Guojian Pharmaceutical
        11.24.1 Shanghai CP Guojian Pharmaceutical Corporation Information
        11.24.2 Shanghai CP Guojian Pharmaceutical Overview
        11.24.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.24.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.24.5 Shanghai CP Guojian Pharmaceutical Recent Developments
    11.25 Shanghai Pharmaceuticals
        11.25.1 Shanghai Pharmaceuticals Corporation Information
        11.25.2 Shanghai Pharmaceuticals Overview
        11.25.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.25.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.25.5 Shanghai Pharmaceuticals Recent Developments
    11.26 Simcere Pharmaceutical
        11.26.1 Simcere Pharmaceutical Corporation Information
        11.26.2 Simcere Pharmaceutical Overview
        11.26.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.26.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.26.5 Simcere Pharmaceutical Recent Developments
    11.27 Toyama Chemical
        11.27.1 Toyama Chemical Corporation Information
        11.27.2 Toyama Chemical Overview
        11.27.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.27.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.27.5 Toyama Chemical Recent Developments
    11.28 Tsumura
        11.28.1 Tsumura Corporation Information
        11.28.2 Tsumura Overview
        11.28.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.28.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.28.5 Tsumura Recent Developments
    11.29 UCB
        11.29.1 UCB Corporation Information
        11.29.2 UCB Overview
        11.29.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.29.4 UCB Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.29.5 UCB Recent Developments
    11.30 Zydus Cadila
        11.30.1 Zydus Cadila Corporation Information
        11.30.2 Zydus Cadila Overview
        11.30.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue and Gross Margin (2017-2022)
        11.30.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
        11.30.5 Zydus Cadila Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Tumor Necrosis Factor Inhibitors Drug Industry Chain Analysis
    12.2 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Tumor Necrosis Factor Inhibitors Drug Production Mode & Process
    12.4 Tumor Necrosis Factor Inhibitors Drug Sales and Marketing
        12.4.1 Tumor Necrosis Factor Inhibitors Drug Sales Channels
        12.4.2 Tumor Necrosis Factor Inhibitors Drug Distributors
    12.5 Tumor Necrosis Factor Inhibitors Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Tumor Necrosis Factor Inhibitors Drug Industry Trends
    13.2 Tumor Necrosis Factor Inhibitors Drug Market Drivers
    13.3 Tumor Necrosis Factor Inhibitors Drug Market Challenges
    13.4 Tumor Necrosis Factor Inhibitors Drug Market Restraints
14 Key Findings in The Global Tumor Necrosis Factor Inhibitors Drug Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Cimzia (Certolizumab Pegol)
    Table 3. Major Manufacturers of Enbrel (Etanercept)
    Table 4. Major Manufacturers of Humira ( Adalimumab)
    Table 5. Major Manufacturers of Otezla (Apremilast)
    Table 6. Major Manufacturers of Remicade (Infliximab)
    Table 7. Major Manufacturers of Simponi (Golimumab)
    Table 8. Global Tumor Necrosis Factor Inhibitors Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 10. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2017-2022) & (K Pcs)
    Table 11. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2017-2022)
    Table 12. Global Tumor Necrosis Factor Inhibitors Drug Sales by Region (2023-2028) & (K Pcs)
    Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2023-2028)
    Table 14. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 15. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2017-2022)
    Table 16. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2023-2028)
    Table 18. Global Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 19. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Manufacturers (2017-2022)
    Table 20. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 21. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Manufacturers (2017-2022)
    Table 22. Tumor Necrosis Factor Inhibitors Drug Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 23. Global Tumor Necrosis Factor Inhibitors Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 24. Global Tumor Necrosis Factor Inhibitors Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2021)
    Table 25. Tumor Necrosis Factor Inhibitors Drug Manufacturing Base Distribution and Headquarters
    Table 26. Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Offered
    Table 27. Date of Manufacturers Enter into Tumor Necrosis Factor Inhibitors Drug Market
    Table 28. Mergers & Acquisitions, Expansion Plans
    Table 29. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)
    Table 30. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2023-2028) & (K Pcs)
    Table 31. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2017-2022)
    Table 32. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2023-2028)
    Table 33. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 34. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 35. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2017-2022)
    Table 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2023-2028)
    Table 37. Tumor Necrosis Factor Inhibitors Drug Price by Type (2017-2022) & (USD/Pcs)
    Table 38. Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 39. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)
    Table 40. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2023-2028) & (K Pcs)
    Table 41. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Application (2017-2022)
    Table 42. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Application (2023-2028)
    Table 43. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 44. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 45. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Application (2017-2022)
    Table 46. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Application (2023-2028)
    Table 47. Tumor Necrosis Factor Inhibitors Drug Price by Application (2017-2022) & (USD/Pcs)
    Table 48. Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 49. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)
    Table 50. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2023-2028) & (K Pcs)
    Table 51. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 52. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 53. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)
    Table 54. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2023-2028) & (K Pcs)
    Table 55. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 56. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 57. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)
    Table 58. North America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2023-2028) & (K Pcs)
    Table 59. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 60. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 61. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)
    Table 62. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2023-2028) & (K Pcs)
    Table 63. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 64. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 65. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)
    Table 66. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2023-2028) & (K Pcs)
    Table 67. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 68. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 69. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)
    Table 70. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Country (2023-2028) & (K Pcs)
    Table 71. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 72. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)
    Table 74. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Type (2023-2028) & (K Pcs)
    Table 75. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)
    Table 78. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Application (2023-2028) & (K Pcs)
    Table 79. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 81. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2017-2022) & (K Pcs)
    Table 82. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Region (2023-2028) & (K Pcs)
    Table 83. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2017-2022) & (US$ Million)
    Table 84. Asia Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Region (2023-2028) & (US$ Million)
    Table 85. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)
    Table 86. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2023-2028) & (K Pcs)
    Table 87. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 88. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 89. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)
    Table 90. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2023-2028) & (K Pcs)
    Table 91. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 92. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 93. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)
    Table 94. Latin America Tumor Necrosis Factor Inhibitors Drug Sales by Country (2023-2028) & (K Pcs)
    Table 95. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 96. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2017-2022) & (K Pcs)
    Table 98. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Type (2023-2028) & (K Pcs)
    Table 99. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2017-2022) & (K Pcs)
    Table 102. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Application (2023-2028) & (K Pcs)
    Table 103. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Application (2023-2028) & (US$ Million)
    Table 105. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2017-2022) & (K Pcs)
    Table 106. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales by Country (2023-2028) & (K Pcs)
    Table 107. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2017-2022) & (US$ Million)
    Table 108. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Country (2023-2028) & (US$ Million)
    Table 109. Apogenix Corporation Information
    Table 110. Apogenix Description and Major Businesses
    Table 111. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 112. Apogenix Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 113. Apogenix Recent Developments
    Table 114. AryoGen Biopharma Corporation Information
    Table 115. AryoGen Biopharma Description and Major Businesses
    Table 116. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 117. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 118. AryoGen Biopharma Recent Developments
    Table 119. Bionovis Corporation Information
    Table 120. Bionovis Description and Major Businesses
    Table 121. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 122. Bionovis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 123. Bionovis Recent Developments
    Table 124. CASI Pharmaceuticals Corporation Information
    Table 125. CASI Pharmaceuticals Description and Major Businesses
    Table 126. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 127. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 128. CASI Pharmaceuticals Recent Developments
    Table 129. Celltrion Corporation Information
    Table 130. Celltrion Description and Major Businesses
    Table 131. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 132. Celltrion Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 133. Celltrion Recent Developments
    Table 134. Celgene Corporation Corporation Information
    Table 135. Celgene Corporation Description and Major Businesses
    Table 136. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 137. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 138. Celgene Corporation Recent Developments
    Table 139. Delenex Therapeutics Corporation Information
    Table 140. Delenex Therapeutics Description and Major Businesses
    Table 141. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 142. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 143. Delenex Therapeutics Recent Developments
    Table 144. Dexa Medica Corporation Information
    Table 145. Dexa Medica Description and Major Businesses
    Table 146. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 147. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 148. Dexa Medica Recent Developments
    Table 149. EPIRUS Biopharmaceuticals Corporation Information
    Table 150. EPIRUS Biopharmaceuticals Description and Major Businesses
    Table 151. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 152. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 153. EPIRUS Biopharmaceuticals Recent Developments
    Table 154. Janssen Biotech Corporation Information
    Table 155. Janssen Biotech Description and Major Businesses
    Table 156. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 157. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 158. Janssen Biotech Recent Developments
    Table 159. GlaxoSmithKline Corporation Information
    Table 160. GlaxoSmithKline Description and Major Businesses
    Table 161. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 162. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 163. GlaxoSmithKline Recent Developments
    Table 164. HanAll Biopharma Corporation Information
    Table 165. HanAll Biopharma Description and Major Businesses
    Table 166. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 167. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 168. HanAll Biopharma Recent Developments
    Table 169. Intas Pharmaceuticals Corporation Information
    Table 170. Intas Pharmaceuticals Description and Major Businesses
    Table 171. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 172. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 173. Intas Pharmaceuticals Recent Developments
    Table 174. LEO Pharma Corporation Information
    Table 175. LEO Pharma Description and Major Businesses
    Table 176. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 177. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 178. LEO Pharma Recent Developments
    Table 179. LG Life Sciences Corporation Information
    Table 180. LG Life Sciences Description and Major Businesses
    Table 181. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 182. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 183. LG Life Sciences Recent Developments
    Table 184. MedImmune Corporation Information
    Table 185. MedImmune Description and Major Businesses
    Table 186. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 187. MedImmune Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 188. MedImmune Recent Developments
    Table 189. Momenta Pharmaceuticals Corporation Information
    Table 190. Momenta Pharmaceuticals Description and Major Businesses
    Table 191. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 192. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 193. Momenta Pharmaceuticals Recent Developments
    Table 194. Novartis Corporation Information
    Table 195. Novartis Description and Major Businesses
    Table 196. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 197. Novartis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 198. Novartis Recent Developments
    Table 199. PROBIOMED Corporation Information
    Table 200. PROBIOMED Description and Major Businesses
    Table 201. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 202. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 203. PROBIOMED Recent Developments
    Table 204. Reliance Life Sciences Corporation Information
    Table 205. Reliance Life Sciences Description and Major Businesses
    Table 206. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 207. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 208. Reliance Life Sciences Recent Developments
    Table 209. Sandoz Corporation Information
    Table 210. Sandoz Description and Major Businesses
    Table 211. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 212. Sandoz Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 213. Sandoz Recent Developments
    Table 214. Samsung Bioepis Corporation Information
    Table 215. Samsung Bioepis Description and Major Businesses
    Table 216. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 217. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 218. Samsung Bioepis Recent Developments
    Table 219. Sanofi-Aventis Corporation Information
    Table 220. Sanofi-Aventis Description and Major Businesses
    Table 221. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 222. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 223. Sanofi-Aventis Recent Developments
    Table 224. Shanghai CP Guojian Pharmaceutical Corporation Information
    Table 225. Shanghai CP Guojian Pharmaceutical Description and Major Businesses
    Table 226. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 227. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 228. Shanghai CP Guojian Pharmaceutical Recent Developments
    Table 229. Shanghai Pharmaceuticals Corporation Information
    Table 230. Shanghai Pharmaceuticals Description and Major Businesses
    Table 231. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 232. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 233. Shanghai Pharmaceuticals Recent Developments
    Table 234. Simcere Pharmaceutical Corporation Information
    Table 235. Simcere Pharmaceutical Description and Major Businesses
    Table 236. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 237. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 238. Simcere Pharmaceutical Recent Developments
    Table 239. Toyama Chemical Corporation Information
    Table 240. Toyama Chemical Description and Major Businesses
    Table 241. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 242. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 243. Toyama Chemical Recent Developments
    Table 244. Tsumura Corporation Information
    Table 245. Tsumura Description and Major Businesses
    Table 246. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 247. Tsumura Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 248. Tsumura Recent Developments
    Table 249. UCB Corporation Information
    Table 250. UCB Description and Major Businesses
    Table 251. UCB Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 252. UCB Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 253. UCB Recent Developments
    Table 254. Zydus Cadila Corporation Information
    Table 255. Zydus Cadila Description and Major Businesses
    Table 256. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 257. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 258. Zydus Cadila Recent Developments
    Table 259. Key Raw Materials Lists
    Table 260. Raw Materials Key Suppliers Lists
    Table 261. Tumor Necrosis Factor Inhibitors Drug Distributors List
    Table 262. Tumor Necrosis Factor Inhibitors Drug Customers List
    Table 263. Tumor Necrosis Factor Inhibitors Drug Market Trends
    Table 264. Tumor Necrosis Factor Inhibitors Drug Market Drivers
    Table 265. Tumor Necrosis Factor Inhibitors Drug Market Challenges
    Table 266. Tumor Necrosis Factor Inhibitors Drug Market Restraints
    Table 267. Research Programs/Design for This Report
    Table 268. Key Data Information from Secondary Sources
    Table 269. Key Data Information from Primary Sources
List of Figures
    Figure 1. Tumor Necrosis Factor Inhibitors Drug Product Picture
    Figure 3. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Type in 2021 & 2028
    Figure 3. Cimzia (Certolizumab Pegol) Product Picture
    Figure 4. Enbrel (Etanercept) Product Picture
    Figure 5. Humira ( Adalimumab) Product Picture
    Figure 6. Otezla (Apremilast) Product Picture
    Figure 7. Remicade (Infliximab) Product Picture
    Figure 8. Simponi (Golimumab) Product Picture
    Figure 9. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Application in 2021 & 2028
    Figure 10. Clinic
    Figure 11. Hospital
    Figure 12. Others
    Figure 13. Tumor Necrosis Factor Inhibitors Drug Report Years Considered
    Figure 14. Global Tumor Necrosis Factor Inhibitors Drug Sales 2017-2028 (K Pcs)
    Figure 15. Global Tumor Necrosis Factor Inhibitors Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Tumor Necrosis Factor Inhibitors Drug Revenue 2017-2028 (US$ Million)
    Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2017-2022)
    Figure 19. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2023-2028)
    Figure 20. North America Tumor Necrosis Factor Inhibitors Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 21. North America Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Europe Tumor Necrosis Factor Inhibitors Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 23. Europe Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 25. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Latin America Tumor Necrosis Factor Inhibitors Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 27. Latin America Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales YoY (2017-2028) & (K Pcs)
    Figure 29. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. The Tumor Necrosis Factor Inhibitors Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 31. The Top 5 and 10 Largest Manufacturers of Tumor Necrosis Factor Inhibitors Drug in the World: Market Share by Tumor Necrosis Factor Inhibitors Drug Revenue in 2021
    Figure 32. Global Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 33. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2028)
    Figure 34. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2017-2028)
    Figure 35. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2028)
    Figure 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2017-2028)
    Figure 37. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2028)
    Figure 38. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2017-2028)
    Figure 39. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2028)
    Figure 40. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2017-2028)
    Figure 41. North America Tumor Necrosis Factor Inhibitors Drug Sales Share by Country (2017-2028)
    Figure 42. North America Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country (2017-2028)
    Figure 43. U.S. Tumor Necrosis Factor Inhibitors Drug Revenue (2017-2028) & (US$ Million)
    Figure 44. Canada Tumor Necrosis Factor Inhibitors Drug Revenue (2017-2028) & (US$ Million)
    Figure 45. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2017-2028)
    Figure 46. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2017-2028)
    Figure 47. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2017-2028)
    Figure 48. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2017-2028)
    Figure 49. Europe Tumor Necrosis Factor Inhibitors Drug Sales Share by Country (2017-2028)
    Figure 50. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Share by Country (2017-2028)
    Figure 51. Germany Tumor Necrosis Factor Inhibitors Drug Revenue (2017-2028) & (US$ Million)
    Figure 52. France Tumor Necrosis Factor Inhibitors Drug Revenue (2017-2028) & (US$ Million)
    Figure 53. U.
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Apogenix
AryoGen Biopharma
Bionovis
CASI Pharmaceuticals
Celltrion
Celgene Corporation
Delenex Therapeutics
Dexa Medica
EPIRUS Biopharmaceuticals
Janssen Biotech
GlaxoSmithKline
HanAll Biopharma
Intas Pharmaceuticals
LEO Pharma
LG Life Sciences
MedImmune
Momenta Pharmaceuticals
Novartis
PROBIOMED
Reliance Life Sciences
Sandoz
Samsung Bioepis
Sanofi-Aventis
Shanghai CP Guojian Pharmaceutical
Shanghai Pharmaceuticals
Simcere Pharmaceutical
Toyama Chemical
Tsumura
UCB
Zydus Cadila
Frequently Asked Questions
Tumor Necrosis Factor Inhibitors Drug report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Tumor Necrosis Factor Inhibitors Drug report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Tumor Necrosis Factor Inhibitors Drug report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Proto-Oncogene Drgu

Proto-Oncogene Drgu market is segmented by Type and by Application. Players, stakeholders, and ot ... Read More